Clinical Trial

Regorafenib Combined With Irinotecan Drug-Eluting Beads for Colorectal Cancer Liver Metastases

Study acronym: RIDER
Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
This study is a multicentre, prospective, randomised trial, aims to evaluate the efficacy and safety of Irinotecan Drug-Eluting Beads combined with regorafenib as the third-line treatment for a patient with colorectal cancer liver metastases. The study is planned to enrolled 126 patients failing first- and second-line standard chemotherapy treatment.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2023-03-20.
Trial Details
NCT Number NCT05794971
Lead Sponsor Sun Yat-sen University
Conditions Colorectal Cancer Liver Metastases, Regorafenib
Enrollment 126 participants
Start Date 2023-06-10
Primary Completion 2027-03-31 (estimated)
Study Completion 2028-03-31 (estimated)
Updated on ClinicalTrials.gov 2023-05-15